

## Azur Pharma Limited

[View the current Azur Pharma Limited Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/19058-Azur+Pharma+Limited.html)

(<http://www.bioportfolio.com/biocorporate/19058-Azur+Pharma+Limited.html>)

### Contact Details:

**45 Fitzwilliam Square  
Dublin 2**

Tel: 353-1-6344-183  
Fax: 353-1-6344-170  
Email:

### Ireland

Azur Pharma is a privately held therapeutically focused pharmaceutical company, headquartered in Dublin, Ireland. We are dedicated to enhancing patient's lives by developing and marketing pharmaceutical products in focused therapeutic areas. Our mission is to create a therapeutically focused pharmaceutical business, sustained through a marketed product portfolio and a product pipeline. Our strategy is to identify, evaluate, selectively acquire and enhance the value of FDA approved, and late-stage development, pharmaceutical assets. Our management team has multiple years of operational, commercial and corporate development experience in the pharmaceutical industry and has developed broad industry relationships.

### Recent Publications by Azur Pharma Limited:



- [Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia.](#)  
*BACKGROUND: This study compared the bioequivalence of FazaClo (clozapine...10th July, 2008 Medical Affairs, Azur Pharma, Inc., Philadelphia, Pennsylvania 19103, USA.- Clin Drug Investig. 2008;28(4):231-9.*

### Press Releases on Azur Pharma Limited:

<a href="#">YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA</a>	23rd November, 2009	YM BioSciences Inc.	MISSISSAUGA, ON, Nov. 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of
<a href="#">Reportlinker Adds Microtomes/Cryostats &amp; Automated Stainers - Global Market Trends</a>	23rd November, 2009	Reportlinker	NEW YORK, Nov. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Microtomes/Cryostats & Automated Stainers - Global Market Trends http:
<a href="#">Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015</a>	23rd November, 2009	Reportlinker	NEW YORK, Nov. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. India Dental Devices Investment Opportunities, Analysis and Forecasts to
<a href="#">Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update</a>	23rd November, 2009	Wound Management Technologies, Inc.	FORT WORTH, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced that it has
<a href="#">Visage Imaging(R) Wins \$1.4 Million Lake Imaging Deal With Visage(R) 7 Enterprise Solution</a>	23rd November, 2009	Visage Imaging Inc.	ANDOVER, Mass., Nov. 23 /PRNewswire-FirstCall/ -- Visage Imaging® Inc., a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME) announced today a signed deal to provide Lake Imaging, one of

**Azur Pharma Limited Clinical Trials:**



- [FazaClo Outcomes in the Control of Schizophrenia \(FOCUS\) Study Survey](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

